This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…
This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Read Post »
What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and the strength of the DrugPatentWatch platform to develop a solution…
The post Make better decisions with advanced biopharmaceutical busin…
Make better decisions with advanced biopharmaceutical business intelligence Read Post »
Joseph E Stiglitz, American economist and professor at Columbia University, states that prizes should be favored over patents to reward and stimulate innovation. The uniqueness of the patent system referred…
The post Driving Innovation: Drug Patents vs…
This paper was originally published by Hanqing Xue, Jie Li, Haozhe Xie, and Yadong Wang in Int J Biol Sci 2018; 14(10):1232-1244 under a Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). Abstract Drug…
T…
Review of Drug Repositioning Approaches and Resources Read Post »
This paper was originally published by Glenn P. Carroll, Sanjay Srivastava, Adam S. Volini, Marta M. Piñeiro-Núñez, and TatianaVetman in Drug Discovery Today Volume 22, Issue 5, May 2017, Pages 776-785 under…
The post Measuring the effectiveness and im…
Measuring the effectiveness and impact of an open innovation platform Read Post »
The story of Viagra’s patents and generic entry of sildenafil citrate is a valuable one because it covers many of the nuances of drug patenting and generic entry in the…
The post Viagra: A Complicated Case Study of Generic Drug Market Entry in the Unit…
Viagra: A Complicated Case Study of Generic Drug Market Entry in the United States Read Post »
Drugs can have many patents and regulatory protections Drugs can be covered by myriad patents and regulatory protections. Even Aspirin, which was first invented in 1853, has new patents. For…
The post Generic Drug Launch Dates – A 1-step Solution to Na…
This is paper was originally published in BioMed Research International, Volume 2016, by Tomas Gabriel Bas and Carolina Oliu Castillo under a Creative Commons Attribution License Abstract The development of…
The post Biosimilars in Developed and Develo…
Although many areas of contention exist in trade relations between the United States and China, ties are strengthening between the two countries, particularly in the areas of science and technology.…
The post China and Potential Opportunity for Pharmac…
China and Potential Opportunity for Pharmaceutical Investments Read Post »
Get new actionable insights and updates from BiotechBlog
